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Next-generation sequencing has contributed to our understanding of the genetics of Alzheimer’s disease
(AD) and has explained a substantial part of the missing heritability of familial AD. We sequenced 19
exomes from 8 Dutch families with a high AD burden and identiﬁed EIF2AK3, encoding for protein kinase
RNA-like endoplasmic reticulum kinase (PERK), as a candidate gene. Gene-based burden analysis in a
Dutch AD exome cohort containing 547 cases and 1070 controls showed a signiﬁcant association of
EIF2AK3 with AD (OR 1.84 [95% CI 1.07e3.17], p-value 0.03), mainly driven by the variant p.R240H.
Genotyping of this variant in an additional cohort from the Rotterdam Study showed a trend toward
association with AD (p-value 0.1). Immunohistochemical staining with pPERK and peIF2a of 3 EIF2AK3
AD carriers showed an increase in hippocampal neuronal cells expressing these proteins compared with
nondemented controls, but no difference was observed in AD noncarriers. This study suggests that rare
variants in EIF2AK3 may be associated with disease risk in AD.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer’s disease (AD) is the most common cause of de-
mentia, characterized by progressive decline in memory and other
cognitive functions (Ballard et al., 2011). Genetic factors are strongly
linked to AD, and in about 5% of cases, an autosomal dominant
mode of inheritance has been reported (St George-Hyslop, 1999). In
autosomal dominant forms of early-onset AD, mutations in b-am-
yloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2
(PSEN2) have been found to be causative genes (Goate et al., 1991;gy, Erasmus Medical Centre
3015 CE Rotterdam, The
van Swieten).
Inc. This is an open access article uLevy et al., 1990; Levy-Lahad et al., 1995; Rogaev et al., 1995;
Sherrington et al., 1995); this accounts for approximately 13% of
early-onset AD (Campion et al., 1999). In late-onset AD, the ε4 allele
of apolipoprotein E gene has been found to be the most common
risk factor (Farrer et al., 1997).
Neuropathologically, the aggregation of misfolded proteins is a
major hallmark of many neurodegenerative disorders (Hetz and
Mollereau, 2014). The accumulations of extracellular amyloid pla-
ques and intracellular neuroﬁbrillary tangles are the hallmarks of
AD (Braak and Braak, 1991). Previous studies suggest that disrupted
protein homeostasis in the endoplasmic reticulum (ER) and acti-
vation of unfolded protein response (UPR) may be major drivers in
AD pathogenesis (Hetz and Mollereau, 2014; Scheper and
Hoozemans, 2015). The UPR is induced by 3 transmembrane pro-
teins in the ER: protein kinase RNA-like endoplasmic reticulumnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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transcription factor 6 (ATF6). Activation of UPR led to transient
suppression of protein synthesis, and increased expression of genes
aimed to restore the homeostasis of the ER (Hetz and Mollereau,
2014). Pharmacological and genetic manipulation of the UPR
pathways in animal studies, in particularly the PERK pathway, has
been reported to inhibit neurodegeneration (Smith and Mallucci,
2016).
Advances in next-generation sequencing technology have
contributed substantially to our understanding of the genetics of
AD. In recent years, studies using whole-exome sequencing (WES)
and whole-genome sequencing reported the association of rare
variants in PLD3, ABCA7, TREM2, and SORL1with an increased risk in
AD (Cruchaga et al., 2014; Cuyvers et al., 2015; Guerreiro et al.,
2013; Holstege et al., 2017; Pottier et al., 2012). Furthermore, a
large exome microarray study identiﬁed rare coding variants in
PLCG2, ABI3, and TREM2, explaining a small part of missing herita-
bility in AD (Sims et al., 2017). These studies indicate the existence
of other rare variants related to the heritability of AD.
In this article, we performed WES in 8 Dutch AD families with
probable autosomal dominant inheritance and identiﬁed eukary-
otic translation initiation factor 2 alpha kinase 3 (EIF2AK3),
encoding for PERK, as a candidate AD risk gene in 2 of these fam-
ilies. Together with previous reports on an increased activation of
PERK in AD brains and the involvement of PERK in memory and
learning (Rozpedek et al., 2015), these ﬁndings suggest the possible
role of EIF2AK3 in the pathogenesis of AD.2. Materials and methods
2.1. Subjects
Our discovery data set included 19 AD patients from 8 Dutch
families with a high AD burden. Each family had at least 2 patients
with AD suggestive of an autosomal dominant inheritance pattern,
except 1 family with an uncertain mode of inheritance due to the
early death of both parents. The mean age at disease onset in the
families varied from 62.5 to 71.3 years (Table 1). Nondemented ﬁrst-
and second-degree family members of each family were also
included if available. Using WES, all patients were screened nega-
tive for mutations in PSEN1, PSEN2, and APP; APP copy number
mutations were also excluded. For WES, we included DNA samples
of at least 2 patients with AD from each family. Nondemented
family members with a minimum age of 65 years were used to test
for segregation in their respective family.
Patients and family members were recruited after referral to the
Department of Neurology in the Erasmus Medical Center or after
visiting (nursing) homes. Diagnosis of probable AD was conﬁrmedTable 1
Baseline characteristics of the families
Family Cases Controls WES cases Mean age at onset (ran
NLAD 1 5 8 3 70.4 (60e89)
NLAD 2 2 2 2 62.5 (52e73)
NLAD 3 5 2 3 71.3 (68e77)
NLAD 4 5 1 2 62.8 (59e65)
NLAD 5 2 0 2 66.0 (NA)
NLAD 6 3 1 3 67.7 (64e70)
NLAD 7 2 3 2 71.0 (66e76)
NLAD 8 2 4 2 64.5 (59e70)
The number of patients and controls included from each family. Cases are the total num
impairment. Controls contain the total number of included individuals without subjective
ﬁrst disease onset of all included cases, and the age at last visits is the mean age of all in
Key: AD, Alzheimer’s disease; NA, not available; WES, whole-exome sequencing.in all patients according to the National Institute of Neurological
and Communicative Disorders and StrokeeAlzheimer’s Disease and
Related Disorders Association criteria for AD (McKhann et al., 2011).
To replicate the association of our candidate gene with AD, we
used exome data available from 547 AD cases and 1070 controls
from 3 different sites (the Rotterdam Study, Amsterdam Dementia
Cohort [ADC-VUmc], and Alzheimer Centrum Erasmus MC [AC-
EMC]) included from a Dutch AD exome data set, previously
described by Holstege et al. (Holstege et al., 2017). We then geno-
typed our candidate variant in 1055 AD cases and 6162 controls
from the Rotterdam Study (Ikram et al., 2017); any individuals from
the Rotterdam Study included in the exome data were excluded for
genotyping.
Our study has been approved by the Medical Ethical Committee
of Erasmus Medical Center, and written informed consent was
obtained from all participants or their legal representatives.2.2. Whole-exome sequencing analysis
Exomes of 19 AD patients from the discovery set, the Rotterdam
Study cohort, and the AC-EMC cohort were captured using the
NimbleGen SeqCap EZ Exome Capture Kit v2. Exomes from the
ADC-VUmc cohort were captured using the NimbleGen SeqCap EZ
Exome Capture Kit v3. All data were generated at the Human Ge-
nomics Facility (HuGeF; www.glimdna.org) at Erasmus MC Rotter-
dam, the Netherlands. DNA from each sample was prepared using
the Illumina TruSeq Paired-End Library Preparation Kit, and 100-bp
paired end reads were acquired by sequencing the libraries on a
HiSeq 2000. For the Dutch exome data set, we used the overlapping
regions between capture kits during calling of the data. Sequencing
reads were aligned to the hg19 human genome assembly using
BWA-MEM (version 0.7.3a) (Li and Durbin, 2009), and Picard Tools
(version 1.9) (Li et al., 2009) were used to mark duplicates and to
sort the alignments. Subsequently, Genome Analysis Toolkit (GATK)
(version 3.3) was used to perform indel realignment and base
quality score recalibration (McKenna et al., 2010). Haplotype-Caller
from GATK was used to create genomic VCF ﬁles and to call variants
from these genomic VCF ﬁles. For the exome data from the 8 fam-
ilies (discovery set), we used hard ﬁlters according to GATK best
practices to ﬁlter out low-quality variants. For the exome data from
the 3 Dutch cohorts, we used variant quality score recalibration
with >99% sensitivity to ﬁlter out low-quality variants. Subse-
quently, Plink was used to calculate principal components (PCs),
and outliers on the ﬁrst 2 PCs were removed (Purcell et al., 2007).
Related individuals with identity-by-descent value > 0.1 were also
removed from the analysis set. All individuals in theWES data were
checked for sex concordance using Plink (Purcell et al., 2007).ge) Mean age at last visits
of controls (range)
% Female APOE fraction ε2/ε3/ε4
69.1 (65e77) 46.2 0.2/0.5/0.3
69.0 (68e70) 50.0 0/0.25/0.75
78.5 (71e86) 71.4 0/0/1
66.7 (61e72) 57.1 0/0.12/0.88
NA 0.0 0/0.75/0.25
69.0 (NA) 75.0 0/0.67/0.33
73.3 (69e78) 20.0 0/0/1
71.4 (70e73) 50.0 0/1/0
ber of included patients with Alzheimer’s disease and patients with mild cognitive
of objective memory impairment during the last visit. Age at onset is the mean age of
cluded controls. Age at onset and age at last visits in years.
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In our discovery set, we used a family-based analysis to identify
candidate genes from the 8 families. Each family was analyzed
separately to identify the candidate variants in their respective
family. We focused on shared variants among the affected family
members, which resulted in an amino acid change. Subsequently,
variants with a frequency of 0.5% or lower in 1000 genomes, NHLBI
Exome Sequencing Project (ESP), Exome Aggregation Consortium
(ExAC), Genome of the Netherlands, and in-house WES data from
the Rotterdam Study were selected (Supplementary Table 1)
(Genome of the Netherlands, 2014; Genomes Project et al., 2015;
Lek et al., 2016; Tennessen et al., 2012; van Rooij et al., 2017). If
the same variant or different variants in the same gene were
identiﬁed in at least 2 families, these variants were selected as
candidates for follow-up and tested with Sanger sequencing for
segregation in their respective families.
2.3. Sanger sequencing
We used Primer 3 (Untergasser et al., 2012) to design primers for
candidate variants. PCR ampliﬁcation was performed using Qiagen
Taq DNA polymerase (Qiagen, CA, USA). Direct sequencing of PCR
products was performed using Big Dye Terminator chemistry ver.
3.1 (Applied Biosystems) and run on an ABI3130 genetic analyzer
and an ABI3730xl genetic analyzer (Applied Biosystems, CA, USA).
The sequences were analyzed with Sequencher software, version
4.5 (Genecodes, VA, USA), and SeqScape, version 2.6 (Applied
Biosystems).
2.4. Genotyping of rs147458427 variant in EIF2AK3
The variant rs147458427 (p.R240H) was genotyped using Taq-
Man SNP Genotyping Assays, and genotypes of rs147458427 were
determined using TaqMan Allelic discrimination. Signals were read
with the TaqMan 7900HT (Applied Biosystems Inc) and analyzed
using the Sequence Detection System 2.4 software (Applied Bio-
systems Inc). To evaluate genotyping accuracy, all heterozygous
calls were typed twice to conﬁrm genotypes. Single-variant asso-
ciation effects for AD association were calculated using R (version
3.2.3) “seqMeta” tool v.1.6.0 adjusting for gender. APOE status was
added as a covariate in the secondary analysis.
2.5. Statistical analysis of the candidate genes in the Dutch exome
data set
Single-variant association effect for AD association was calcu-
lated using R (version 3.2.3) “seqMeta” tool v.1.6.0 adjusting for
gender. Burden test was calculated for our top candidate gene in the
family-based analysis using burdenMeta function in “seqMeta” tool
v.1.6.0. Only variants with minor allele frequency (MAF)  1% in
ExAC were included in the burden test, adjusting for gender. In the
secondary analysis, we performed these analyses on our top
candidate gene, adjusting for gender and APOE status.
2.6. Histology and immunohistochemistry
The Netherlands Brain Bank performed brain autopsy according
to their Legal and Ethical Code of Conduct. Tissue blocks of 3 EIF2AK3
carriers (2 from family NLAD1 and 1 from family NLAD4)were taken
from all cortical areas, hippocampus, amygdala, basal ganglia, sub-
stantia nigra, pons, medulla oblongata, cerebellum, and cervical
spinal cord. They were embedded in parafﬁn blocks and subjected to
routine staining with hematoxylin and eosin, periodic acideSchiff
reaction, and silver staining. Immunohistochemistry wasperformed with antibodies directed against phosphorylated
pancreatic endoplasmic reticulum kinase (pPERK) (sc-32577; Santa
Cruz biotechnology, CA; 1:12,800) and phosphorylated eukaryotic
initiation factor-2a (peIF2a) (SAB4504388; Sigma-Aldrich, St. Louis,
MO; 1:100). We performed staining of pPERK and peIF2a on the
frontal, temporal, and hippocampal regions of our 3 pathological-
conﬁrmed AD EIF2AK3 carriers, 3 AD noncarriers, and 3 non-
demented controls. Immunohistochemical staining of the neurons
with pPERK and peIF2a was scored with a semiquantitative method
using a modiﬁed version of the scale developed by Stutzbach et al.
and Hoozemans et al.: Negative (): no cells stained, rare (þ):
1e3 cells stained, þþ: 4e20 cells stained or up to 10 percent of cells
stained, þþþ: 20þ cells stained or 11 to 30 percent of cells stained,
and þþþþ: high density of stained cells (>30 percent) in almost
every ﬁeld of the section (Stutzbach et al., 2013) (Hoozemans et al.,
2009). In the frontal and temporal regions, the average number of
positive stained cells per ﬁeld was counted in 9 different ﬁelds of the
cortical layer at 20x magniﬁcation. In the hippocampus, we used a
different scoring method as this region is often severely affected in
AD with extensive neuronal loss. We counted the total number of
neurons with a nucleus, as well as the number of these neurons
containing pPERK or peIF2a staining to calculate the percentage of
stained neurons. We focused on the cornu ammonis 1 (CA1) and
subiculum, as these contain the largest number of positive stained
cells and calculated the average percentage of stained cells per ﬁeld
in 3 different ﬁelds of CA1 and subiculum, each at 40x magniﬁcation.
We used Mann-Whitney U test to examine the difference be-
tween AD EIF2AK3 carriers and noncarriers. All tests are 2-sided
signiﬁcant tests, and a p-value below 0.05 was assumed as being
statistically signiﬁcant.
2.7. Immunoblot analysis
Postmortem fresh-frozen brain tissue of the frontal cortex from
3 carriers of EIF2AK3 mutations (III:15 and III:18 from family NLAD
1, and III:7 from family NLAD 4, Supplementary Fig. 1) and 3 AD
cases were extracted with buffers of increasing strength (Neumann
et al., 2006). Brieﬂy, gray matter was extracted at 5 mL/g (volume/
weight) using low salt buffer (10mMTris, pH 7.5, 5 mMEDTA,1mM
DTT, 10% sucrose, and a cocktail of protease inhibitors), high salt-
Triton buffer (low salt þ 1% Triton X-100 þ 0.5 M NaCl), myelin
ﬂoatation buffer (30% sucrose in low salt þ 0.5 M NaCl), and sar-
kosyl (SARK) buffer (1% N-lauroylsarcosine in low salt þ 0.5 M
NaCl). The SARK insoluble material was extracted in 0.25 mL/g urea
buffer (7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl) dime-
thylammonio]-1-propanesulfonate {CHAPS}, 30 mM Tris, pH 8.5).
Proteins were resolved by 7.5% SDS-PAGE and transferred to poly-
vinylidene diﬂuoride membranes (Millipore). Following transfer,
membranes were blocked with Tris-buffered saline containing 3%
powdered milk and probed with the antibody p-PERK (sc-32577;
Santa Cruz). Primary antibodies were detected with horseradish
peroxidaseeconjugated anti-mouse or anti-rabbit IgG (Jackson
ImmunoResearch), and signals were visualized by a chemilumi-
nescent reaction (Millipore) and the Chemiluminescence Imager
Stella 3200 (Raytest).
3. Results
3.1. Family-based exome analysis of the discovery set
In our discovery analysis of 19 AD patients from 8 families, we
found an average of 91 (range 26e136) candidate variants per
family after ﬁltering (Supplementary Table 1). Combining the
candidate variants of the 8 families, we found 101 variants in 36
candidate genes, with some genes showing many variants shared
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genes as potential candidates as these are reported as frequent
hitters in many WES data sets (Fuentes Fajardo et al., 2012). We
selected the gene EIF2AK3, encoding for pancreatic endoplasmic
reticulum kinase (PERK) as a top candidate gene (Sherrington et al.),
based on its involvement in memory and learning, and on its
neurodegenerative role in AD and other neurodegenerative dis-
eases (Ohno, 2018; Scheper and Hoozemans, 2015).
The ﬁrst EIF2AK3 variant, p.R240H (rs147458427), was heterozy-
gous in 4 affected individuals (including 1 with mild cognitive
impairment) of family NLAD 1, and in 1 nondemented, 72-year-old
cousin of the proband (Supplementary Fig. 1). This variant had a
CADD score of 31 and a frequency of 8.00 1004 in ExAC. The second
EIF2AK3 variant, p.N286S (rs150474217), had a low CADD score of
0.002 and a frequency of 3.00 1005 in ExAC andwas conﬁrmed in 4
patientswith AD from family NLAD4 and in 1 nondemented, 72-year-
old individual at last visit. One sibling with memory complaints and a
normal MinieMental State Examination score did not carry the
variant. Two of three patients with AD in family NLAD 4 carried ho-
mozygous APOE ε4; the third patient was heterozygous for APOE ε4.
All patients were diagnosed with early-onset AD.
Sanger sequencing on the remaining variants in the 32 candi-
date genes shared among the 8 families (MUC genes excluded)
conﬁrmed variants in 15 genes (Supplementary Table 2). Segrega-
tion analysis of the variants in these 15 genes in their respective
family did not show perfect segregation for most variants; the
segregation in some variants could not be tested due to limited
samples from related individuals.
3.2. Evaluation of EIF2AK3 variants in Dutch cohorts
To determine the genetic association of EIF2AK3 in AD, we per-
formed gene-based burden analysis of EIF2AK3 variants on the
Dutch AD WES data set. We detected 23 EIF2AK3 variants in this
data set (Fig. 1 and Supplementary Table 3), of which 19 had an
allele frequency <1% in ExAC; 17 of these rare variants were
missensemutations. Burden test of all variants in EIF2AK3withMAF
<1% in ExAC showed an increased risk for AD (OR ¼ 1.84; 95% CI
1.07e3.17, p ¼ 0.03). Single-variant analysis showed more carriers
of variant p.R240H in cases (OR ¼ 4.22; 95% CI 1.06e16.80, p ¼
0.04), but the nominal signiﬁcant difference did not sustain the
Bonferroni correction (Supplementary Table 3). We then performed
a second analysis with APOE as an additional covariate showing the
frequency of EIF2AK3 carriers with at least one copy APOE ε4 is 62%
(16/26). The single-variant analysis of p.R240H (OR¼4.47, p ¼ 0.04)Fig. 1. Schematic representation of EIF2AK3 gene and relative position of the EIF2AK3 var
composed of a signal peptide, a regulatory domain, and a catalytic domain. Variants highligh
color in this ﬁgure legend, the reader is referred to the Web version of this article.)and the burden analysis (OR ¼ 1.9, p ¼ 0.025) were similar to the
analysis without APOE as a covariate.
As the variant p.R240H showed a suggestive signal with a high
CADD score, we genotyped this variant in an independent cohort
from the Rotterdam Study containing 1055 cases and 6162 controls.
We found an increased frequency in AD cases compared with
controls (OR¼ 3.03; 95% CI 0.78e11.48, p¼ 0.10), and an association
with AD after adjusting for APOE as an additional covariate (OR ¼
2.57; 95% CI 0.69e9.51, p¼ 0.16); however, in both cases, the results
were not statistically signiﬁcant.
3.3. Immunohistochemistry and immunoblot analysis
In our EIF2AK3 carriers, many neurons with positive staining for
pPERK and peIF2a were seen in the hippocampus, as well as a low
tomoderate number of positively stained neurons in the frontal and
temporal cortex (Table 2). The activated pPERK and peIF2a staining
in neurons were punctate shaped and were located in the cyto-
plasm, as reported in previous studies (Fig. 2AeF) (Hoozemans
et al., 2009; Stutzbach et al., 2013). One carrier (III:18) from fam-
ily 1 had severe neuronal loss in the CA regions and subiculum.
Overall, the staining of peIF2a was more prominent than pPERK
(Fig. 2A and D). All elderly nondemented controls showed a low to
moderate degree of pPERK staining in the hippocampus. EIF2AK3
carriers had signiﬁcantly more positive staining than nondemented
controls in the hippocampus (p ¼ 0.04) and temporal region (p ¼
0.03). For peIF2a, a trend for more positive staining was only
observed in the hippocampus of EIF2AK3 carriers compared with
nondemented controls (p ¼ 0.07). We found no difference in all
examined regions when comparing EIF2AK3 carriers with AD non-
EIF2AK3 carriers; all EIF2AK3 carriers had Braak stage 6 with
extensive tau pathology in the hippocampus, frontal, temporal, and
parietal cortices.
We used Western blot analysis with a series of buffers with
increasing strength to solubilize proteins to investigate biochemical
alteration of pPERK. One band of approximately 140 kDa in low salt,
representing pPERK, was found in both EIF2AK3 mutation carriers
and AD cases. We found no differences in banding and solubility of
pPERK between carriers of EIF2AK3 and AD non-EIF2AK3 carriers
(Supplementary Fig. 2).
4. Discussion
This is the ﬁrst study to investigate the role of rare variants in
EIF2AK3 in patients with AD.We performedWES in 8 Dutch familiesiants found in the present study. The gene EIF2AK3 contains 1116 amino acids and is
ted in red are found in the family-based analysis. (For interpretation of the references to
Table 2
Scoring of inclusions for peIF2a and pPERK antibodies
ID Braak stage Age at death PMD peIF2a pPERK
Frontal Temporal Hippocampus Frontal Temporal Hippocampus
Carrier III:15 (R240H) 6 83 5:30  þþ þþþþ  þ þþþ
Carrier III:18 (R240H) 6 91 4:20 þ þþ þþþ þ þ þþþþ
Carrier III:7 (N286S) 6 70 6:20 þ þþþ þþþþ þ þþ þþþþ
AD non-EIF2AK3 carrier 1 5 95 7:00 þ þþ þþþþ  þ þþþ
AD non-EIF2AK3 carrier 2 5 62 4:40 þ þþþ þþþþ  þ þþþ
AD non-EIF2AK3 carrier 3 5 71 5:50 þ þ þþþþ   þþþ
ND control 1 4 96 4:10  þþ þþþ   þþ
ND control 2 2 80 4:25  þþ þþ   þþ
ND control 3 2 90 5:45  þ þþ   þ
Semiquantitative scoring of inclusions for peIF2a and pPERK for carriers with EIF2AK3 variants, AD non-EIF2AK3 controls and ND controls.
Key: , negative; þ, rare; þþ, low density (up to 10%); þþþ, moderate density (11%e30%); þþþþ, high density (>30%); AD, Alzheimer’s disease; ND, nondemented; PMD,
postmortem delay.
Fig. 2. Immunohistochemical staining of pPERK and peIF2a in the AD cases with EIF2AK3 mutations. Activated pPERK and peIF2a was found in the hippocampus and te
regions (AeF). High numbers of pPERK stained cells were observed in the cornu ammonis (A) and subiculum (B) of the hippocampus, and lesser numbers were found in the te
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gene in 2 families. Subsequently, gene-based analysis in an inde-
pendent Dutch WES cohort showed suggestive association of
EIF2AK3 with AD. These effects seemed to be mainly driven by
variant p.R240H. Although pPERK and peIF2a staining was more
prominent in EIF2AK3 carriers than in controls, it was similar to AD
non-EIF2AK3 carriers.
We identiﬁed 2 distinct variants in EIF2AK3 segregating with AD
in 2 different families, although unaffected carriers found in each
family suggested incomplete penetrance; however, they may still
develop AD at an older age. The association of an EIF2AK3 variant
with AD has been reported previously, wherein 1 SNP (rs7571971)
in EIF2AK3 was associated with AD in APOE ε4 carriers, but not in-
dependent of APOE (Liu et al., 2013); however, to date, no studies
have examined the association of rare variants in EIF2AK3 with the
risk of AD. The gene burden test of EIF2AK3 in our Dutch AD exome
data set supported this association of rare variants with AD
(p¼0.03), in which it was mainly driven by the variant p.R240H
with a CADD score of 31, but we were unable to conﬁrm the asso-
ciation between p.R240H and AD in an additional cohort from the
Rotterdam Study, although there was a trend toward association
with AD. A possible explanation for the lack of signiﬁcance is the
relatively small sample size for this rare variant. Notably, the high
frequency of APOE ε4 carriers among the EIF2AK3 carriers in the 2
families and in the Dutch AD exome data set further support an
association of EIF2AK3 variants with AD in APOE ε4 carriers as
indicated by Liu et al. (Liu et al., 2013), although similar results were
found for the association tests with and without APOE as covariate.
Studies with larger sample sizes are needed to examine the effects
of rare variants in EIF2AK3 on the risk of developing AD.
The potential signiﬁcance of EIF2AK3 variants in our families also
lies in the fact that PERK is a transmembrane protein involved in
learning, memory, and UPR (Devi and Ohno, 2014; Rozpedek et al.,
2015). Our hypothesis was that variants in EIF2AK3 may enhance
PERK signaling, resulting in increased phosphorylation of tau by
glycogen synthase kinase 3b (GSK3b) and amyloidogenesis (by
beta-secretase 1 [BACE1]). Previous studies have indicated that
PERK-eIF2a signaling is involved in the modulating of tau phos-
phorylation and APP processing in AD (Devi and Ohno, 2014;
Hoozemans et al., 2009; Nijholt et al., 2013), but that it is also
correlated with the level of tau pathology in progressive supra-
nuclear palsy and AD (Hoozemans et al., 2009; Stutzbach et al.,
2013). pPERK immunoreactivity also colocalized with GSK3b in
neuronal cells, which is involved in tau phosphorylation
(Hoozemans et al., 2009; Nijholt et al., 2013). Treatment with a
PERK inhibitor (GSK2606414) in transgenic mice with fronto-
temporal lobar degeneration and overexpression of p.P301L mu-
tation resulted in reduced GSK3b levels and tau phosphorylation
compared with transgenic mice without PERK inhibitor treatment
(Radford et al., 2015). Moreover, PSEN1 (5XFAD)-mutated mice with
PERK haploinsufﬁciency had lower levels of BACE1 than those with
normal PERK levels, resulting in lower amyloid-beta peptide levels
and plaque burden, as well as fewer memory deﬁcits and cholin-
ergic neurodegeneration (Devi and Ohno, 2014). Reduced synaptic
plasticity and spatial memory deﬁcits were found in the APP/PS1
AD mice model with PERK haploinsufﬁciency (Ma et al., 2013).
Although these studies supported a role of PERK signaling in the
pathogenesis of AD, functional experiments are needed to conﬁrm
the effect of EIF2AK3 variants.
The increase of PERK-eIF2a signaling in the EIF2AK3 carriers is
supported by the more positive staining of pPERK and peIF2a
compared with nondemented controls, indicating an increased
activation of UPR. This increased UPR has also been observed in AD
and progressive supranuclear palsy patients in previous studies
(Hoozemans et al., 2005; Stutzbach et al., 2013). However, we didnot ﬁnd any differences in pPERK and peIF2a staining between
EIF2AK3 carriers and AD non-EIF2AK3 carriers, suggesting EIF2AK3
mutation carriers might not induce more UPR activation than other
AD patients. A possible explanation is that EIF2AK3 mutation car-
riers may trigger UPR activation early in the disease process,
without the ability to observe this at the end-stage AD.
The main limitation of our study is the family-based analysis
used to identify the candidate genes; we only selected genes con-
taining rare variants in at least 2 families for follow-up. We cannot
rule out the possibility that other possible candidates in the families
were missed. However, this method has previously been success-
fully used by Cruchaga et al., resulting in the identiﬁcation of the
genetic association of PLD3 with AD (Cruchaga et al., 2014).
Furthermore, EIF2AK3 was the only gene in our candidate list
involved in the pathogenesis of AD. Another limitation is the
limited available samples of related cases and (old) nondemented
controls in some families to analyze segregation; some non-
demented controls may still develop dementia at older age. Finally,
the frequency of APOE ε4 is high in some families, and APOE ε4
segregates with the disease in some of them. This is also true for
family 4, in which variant p.N285S was found; 4 patients and 1
individual with memory complaints carried at least 1 copy of APOE
ε4. However, all 4 patients carrying p.N285S and APOE ε4 had early-
onset AD, indicating a possible additional effect of genetic variation
in EIF2AK3 on the risk of AD among APOE ε4 carriers, as indicated in
a previous study (Liu et al., 2013). Future analyses in larger case-
control studies are necessary to conﬁrm this association.
In conclusion, our study showed that rare variants in EIF2AK3
may be associated with an increased risk of AD based on segrega-
tion among the patients with AD in 2 families and a gene-based
analysis in the Dutch WES cohort. Immunohistochemistry
conﬁrmed more activation of UPR, characterized by increased
pPERK and peIF2a in AD patients compared with nondemented
controls, but not between EIF2AK3 carriers and AD noncarriers.
Further studies are needed to investigate the full contribution of
rare variants in EIF2AK3 in the development of AD.Disclosure statement
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